A June 2021 review of early RECOVERY results for casirivimab and imdevimab in hospitalised COVID-19 patients. It explains the reported mortality benefit in patients without detectable antibodies, why that finding did not extend to the whole trial population, and the preliminary evidence available then.
REGN monoclonal antibodies work in selected hospitalised COVID-19 patients. St Emlyn’s Read More
A June 2021 look at the first RECOVERY results for aspirin in hospitalised COVID-19 patients. The review considers the absence of a demonstrated mortality benefit, the balance between bleeding and thrombotic events, and the limits of the early results.
JC: Aspirin is not effective for hospitalised COVID19 patients. St Emlyn’s Read More
A March 2021 appraisal of anticoagulation trials in critically ill patients with COVID-19. Simon Carley and Dan Horner examine therapeutic-dose versus usual-care thromboprophylaxis, organ support outcomes and bleeding, explaining why the findings cannot simply be extended to ward patients or treatment of confirmed thrombosis.
JC: Thromboprophylaxis on the ICU for COVID-19 patients. St Emlyn’s Read More
Iain and Simon revisit February 2021 on the St Emlyn’s blog and podcast. The accompanying article links cover TIA risk assessment, proposed emergency care standards, tocilizumab evidence, TXA for epistaxis and conversations with patients about COVID-19 risk.
Podcast – February 2021 Monthly Round Up Read More
A March 2021 review of the RECOVERY convalescent plasma preprint in hospitalised patients with COVID-19. It examines the absence of a survival benefit, donor antibody testing and subgroup findings, and reflects on why promising treatments still need randomised evidence.
JC: Convalescent plasma (still) does not work in COVID-19. St Emlyn’s Read More
A March 2021 update on RECOVERY’s initial colchicine results in hospitalised patients with COVID-19. It reports the lack of a mortality benefit announced at the time, distinguishes these patients from community cases and notes that the full paper was still awaited.
Colchicine does not improve mortality in COVID19. St Emlyn’s Read More
Dan Horner takes a detailed look at the February 2021 RECOVERY tocilizumab preprint. The appraisal examines reported survival benefits alongside patient selection, incomplete follow-up, absolute versus relative effects and the uncertainties that remained behind the optimistic headlines.
Tocilizumabulous? A special offer on IL-6 with Tocilizumab. Read More
The first February 2021 report of RECOVERY’s tocilizumab results, written as the announcement and preprint emerged. Simon Carley and Dan Horner outline the reported benefits in hospitalised patients with hypoxia and inflammation, while flagging the need for fuller appraisal and questions about immunosuppression.
JC: RECOVERY trial shows Tocilizumab effective for COVID19. St Emlyn’s Read More
